Loading clinical trials...
Loading clinical trials...
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Conditions
Interventions
B/F/TAF
NRTIs
+1 more
Locations
82
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Alabama Medical Group, PC
Mobile, Alabama, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Ruane Clinical Research Group Inc.
Los Angeles, California, United States
Mills Clinical Research
Los Angeles, California, United States
Highland Hospital- Alameda Health System
Oakland, California, United States
Start Date
August 28, 2018
Primary Completion Date
August 12, 2019
Completion Date
August 19, 2020
Last Updated
September 5, 2021
NCT06660498
NCT06602622
NCT05729568
NCT06185452
NCT06902038
NCT04568603
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions